383 related articles for article (PubMed ID: 28789760)
1. [Antithrombotic treatment of patients with valvular atrial fibrillation].
Bovin A; Christensen TD; Grove EL
Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
[TBL] [Abstract][Full Text] [Related]
2. How to define valvular atrial fibrillation?
Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
[TBL] [Abstract][Full Text] [Related]
3. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
De Caterina R; John Camm A
Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.
Caldeira D; David C; Costa J; Ferreira JJ; Pinto FJ
Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):111-118. PubMed ID: 28950374
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
7. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
8. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
[TBL] [Abstract][Full Text] [Related]
9. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
[TBL] [Abstract][Full Text] [Related]
10. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
Di Pasquale G; Zagnoni S; Riva L
Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
[TBL] [Abstract][Full Text] [Related]
11. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
Renda G; Ricci F; Giugliano RP; De Caterina R
J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
[TBL] [Abstract][Full Text] [Related]
12. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.
Al-Najar M; Al-Nusair M; Alrabadi N; Alawaisheh I; Alawaisheh T; Jarrah M; Alzoubi KH; Njem S; Hamoudeh A
Vasc Health Risk Manag; 2023; 19():145-155. PubMed ID: 36968249
[TBL] [Abstract][Full Text] [Related]
15. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
17. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study.
Lee SR; Choi EK; Han KD; Cha MJ; Oh S; Lip GYH
PLoS One; 2017; 12(12):e0189495. PubMed ID: 29261716
[TBL] [Abstract][Full Text] [Related]
18. Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso.
Yameogo AR; Kologo JK; Mandi G; Kabore HP; Millogo GR; Seghda AA; Samadoulougou AK; Zabsonre P
Pan Afr Med J; 2016; 24():108. PubMed ID: 27642447
[TBL] [Abstract][Full Text] [Related]
19. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
[TBL] [Abstract][Full Text] [Related]
20. Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants-A Systematic Review.
Russo V; Bottino R; Rago A; Micco PD; D' Onofrio A; Liccardo B; Golino P; Nigro G
Semin Thromb Hemost; 2019 Mar; 45(2):205-214. PubMed ID: 30119139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
